List of Therapeutic Companies in New Jersey - 116

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

An early stage start-up with three products in Pre-IND phase and several complex generics in the pipeline.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Althera is focused on development and supply of innovative patient focused medicines. Althera’s medicines are approved and available to patients in more than 35 countries worldwide. ​Founded in 2010, we are leaders in development of innovative combination medicines in therapeutic areas of Cardiology and Diabetes, and work closely with our B2B partners in making these products available to patients in geographies across the world including all major markets in Europe and Emerging Markets including Asia, Latin America and Africa. ​Our strong R&D capabilities and network of manufacturing sites enable innovative and cost effective supply of medications to improve patient health.

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people's lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc (www.rkpharmainc.com), is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full suite of R&D, QA, QC, and Manufacturing Services. This facilitates a continuous real-time exchange of information, ideas, and data while eliminating redundancies and waste. Our managing partners have over 60 years worth of experience in the pharmaceutical world, encompassing small, mid and large pharmaceutical companies throughout the world. Our Mission is to develop, manufacture, and deliver API’s, with superior quality and regulatory support, at competitive costs.

API Pharmatech is focused on delivering Quality therapeutic products, satisfying Regulatory and Statutory necessities thereby, ensuring safety and purity to its products. We indulged in developing and manufacturing generic and innovative APIs and FDFs. Well capable of resources and expertise to pull out an API from development to commercial scale manufacturing, fulfilling all the required statutory regulations and inspections and involving in the development, manufacturing and marketing of the drug. API Pharmatech constantly updates its knowledge and identifies niche and complex APIs and FDFs which are technologically challenged.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

ASCEND Therapeutics US, LLC is a specialty pharmaceutical company concentrating on women’s health. With a century of innovation originating with our parent company, Besins Healthcare, ASCEND Therapeutics continues to attain high standards in commercial and product development. ASCEND THERAPEUTICS U.S., LLC is a pharmaceuticals company based out of 15 Mt Kemble Ave Morristown, NJ 07960

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology-based company focusing on the development and commercialization of Branded Specialty Products and Technology Platform-based Niche Generics. Aucta is a pharmaceutical company creating enhanced products from proven molecules using the 505(b)(2) regulatory pathway. Through innovation, Aucta is creating new therapeutics, including new dosage forms, new dosing regimens, and new indications. Aucta has a clear therapeutic focus in CNS disorders, Ophthalmic, and Inhalation Therapy. We are committed to being patient-centric by continuously bringing improved forms of proven molecules into the marketplace. Aucta has operation in both New Jersey, U.S. and Shanghai, China. Our mission: Enhanced products from proven molecules!

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders. Targeting these therapeutic areas with significant unmet medical needs, we apply innovative science to unveil potentially paradigm shifting immunological pathways in the hope to transform the treatment for millions of patients. We consider it our mission to tackle these diseases from their root cause(s) and aim to reach the goal of relieving patients from the disease burden.

Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes and the Company intends to explore these and other compounds for the treatment of additional pain indications.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

DiamiR developsand diagnostictechnology based on analysis of brain-enriched microRNA biomarkers in blood plasma.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

In 2005, we were founded on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren’t happy with. Because different modalities of neuromodulation had previously proven to be effective and safe, we recognized an opportunity to be the leader in this new frontier of medicine and took it head on. Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments. Bringing new treatments to market will help improve patients'​ treatment options and lives.

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Elite Pharmaceuticals is a pharmaceutical company that specializes in drug manufacturing and healthcare solutions.

Endomedix is a development stage, Medical Device venture, a C corp. The Company has developed a tunable polysaccharide platform that can produce a family of new biomaterials. The first spinoff of this platform is PlexiClot™ Absorbable Hemostat to control bleeding in brain & spinal surgeries, a $1.9B market. PlexiClot introduces the first fundamental innovation in bleeding control in these procedures since the current standard of care was introduced in 1945. The innovation is based on new mechanisms of action that will likely obsolete the current methods of relying on the biochemical action of thrombin and manual pressure to produce coagulation. PlexiClot will eliminate one cause of reoperations caused by current devices as documented in dozens of clinical publications. In addition to reducing the incidence of complications, PlexiClot is poised to save hospitals hundreds of millions of dollars in unreimbursed costs due to reoperation, lengthy hospital stays and early readmission to hospitals. PlexiClot's performance has been confirmed in 3 large animal trials, and Endomedix is currently planning to scale up production. PlexiClot's composition of matter, method of manufacture and mechanisms of action are protected by 8 issued patents, the most important of which expire in 2038. The Endomedix team is led by Richard Russo, a medical device vet with experience in prior start-ups with exits, and he is the lead cash investor. He has a history of success with new products, clinical & regulatory, and international. R&D is led by Piyush Modak, who leverages a small internal team through a constellation of renown subject matter experts. 18 neurosurgeons & physicians are investors. PlexiClot will be the 1st device approved by FDA specifically for brain surgery. This sector is marked by a high level of M&A activity, much of which occurs prior to final FDA approval. The program has drawn interest & support from surgeons and physicians, 18 of whom are investors.

Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company's initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho's assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company's pipeline.

Powering relentless science by developing and commercializing first-in-class treatments to address debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS or cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 Excelra's interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. 𝗙𝗿𝗼𝗺 𝗖𝗵𝗮𝗼𝘀 𝘁𝗼 𝗖𝗹𝗮𝗿𝗶𝘁𝘆: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. 𝗖𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗚𝗼𝗮𝗹𝘀 Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Biotech company specializing in drug discovery for hematologic diseases

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

WHO WE ARE iQure Pharma is uniquely positioned in developing new therapeutics solutions by bridging inventions stemming mostly from academia research with pharma industry, founded by entrepreneurs with strong pharmaceutical and financial industry background. OUR CORE COMPETENCIES Scouting for innovative compounds coming out of research from unmined academic sources. Evaluating out-licensing opportunities with big pharma and biotech for medical and commercial attractive targets. Selecting from that pool those compounds with a significant attractive target profile, which can support a future commercialization process. Driving and leading preclinical and clinical development activities, ensuring regulatory and quality compliance in all development tasks, while never losing focus on the final beneficiaries’ needs: the patients. Securing the required investment activities by assisting our investors in placing their funding in the most commercially viable therapies with attractive market potential and addressing clearly defined clinical needs.

iVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative therapies for clear vision and healthier eyes.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

JOGO Health uses wearable sensors and AI to treat chronic pain, migraine, post-stroke, and pelvic floor disorders using the foundational science of digital therapeutics.

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Kamat Phamatech LLC is a privately held technology-based pharmaceutical company located in Central New Jersey. We specialize in the development, manufacturing, and approval of novel parenteral and enteral products and processes, particularly in the areas of new chemical and biological entities for treatments of various indications.

Kashiv BioSciences manufactures drug delivery systems and specialty drug products for the treatment of debilitating diseases.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including SARS-CoV-2. Lactiga has earned awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics has been granted Orphan Drug Designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

LipoSeuticals is a specialty pharmaceutical company that engages in the development, manufacturing and commercialization of parenteral drug products.

(Formally Caladrius Biosciences; NASDAQ: CLBS) Lisata Inc., (LSTA) a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

MakroCare is expert Regulatory Consulting and Clinical Services partner for pharmaceutical, biotechnology and medical device industries. Our global/regional teams and fit-for-purpose costing models to your development strategy, regulatory management, clinical research, medical/scientific support and quality assurance areas. MakroCare has operations and presence in US, UK, EU, and Asia.

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Mestastop Solutions is a biotechnology startup based in India, focused on addressing cancer metastasis. The company aims to develop innovative solutions to combat the spread of tumors, which significantly contributes to cancer-related deaths worldwide. Mestastop has gained global recognition for its research, presenting its work at major international conferences such as the American Association of Cancer Research Annual Conference and the European Association of Cancer Research. The company is involved in diagnostics and discovery related to cancer metastasis, with a focus on small molecule drugs to tackle distant metastasis. Mestastop's approach includes unraveling the biology of metastasis to create targeted treatments. The company has been vetted by the scientific outsourcing platform Science Exchange and is recognized as an authorized service provider, underscoring its credibility in the field.

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Neurotez Inc. is a biotechnology company focused on developing a Leptin product as a hormone replacement therapy for Alzheimer's disease. Their mission is to become world leaders in biotechnology, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs.

Notitia ("NO-TEE-SHA") means "data" in Latin. We are a microbiome company that applies a data-driven approach to develop innovative products for the ecological restoration of a healthy gut microbiome.  Our mission is to promote health by protecting and/or restoring the Foundation Guild™ of the gut microbiome. Our vision is to maximize everyone's healthspan by keeping their gut microbiome to the healthiest possible status for the longest possible time. The work of Dr. Liping Zhao, co-founder of Notitia, shows that a healthy gut microbiome is dominated by a specific group of beneficial bacteria named the "Foundation Guild." The Foundation Guild™ not only produces beneficial compounds essential to human health but also creates an environment that can suppress the overgrowing pathogens. Restoration and maintenance of the Foundation Guild™ are fundamental to improve health and wellness in patients with unmet medical needs and the generally healthy population. Notitia has developed a revolutionary Foundation Guild™ R&D platform which consists of three technologies: identification, isolation & preservation, and nutritional formulas to support the Foundation Guild™ bacteria. Notitia has created several products based on the Foundation Guild™ R&D platform for patients as well as for the generally healthy population. Foundation Guild™ Wellness Program: a monthly subscription service that provides: 1. Guild:Plus microbiome nutrition 2. Guild:Health data tracking portal 3. Guild:Quest microbiome test kit 4. Guild:Save bio-banking 5. Guild:Pro personalized family-based probiotics. Foundation Guild™ Clinical Program: 1. NBT-NM108, a botanical drug for promoting the Foundation Guild, currently available in a phase 2 trial for COVID-19 and expanded access programs. Additional trials for MS, DKD, Cancer, and Parkinson's will be available by Dec 2021. 2. NBT-BM306, a live biotherapeutic product for restoring the Foundation Guild. Phase 1 trial will be available by Dec 2021.

NovaRock Biotherapeutics is an innovative and dynamic biotech company focusing on the development of antibody therapies for cancer and autoimmune diseases. NovaRock was founded in January 2018 in Princeton, New Jersey by a team of veteran scientists with proven track records in the advancement of biologics from discovery to commercialization.

Novelstar Pharmaceuticals Inc., founded in August, 2018, is a Company of Fosun Pharma focusing on the development of special pharmaceutical products of NDA and ANDA with advanced drug delivery systems. Our parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is a leading health and medical industry group in China. Fosun Pharma has a mission to promote human health. Its business covers the whole pharmaceutical industry chain, including drug manufacturing and R & D, medical services, medical device and medical diagnostics, pharmaceutical distribution and retail. Fosun Pharma has a state-of-the-art innovative technology center and an international R & D team. It continuously focuses on innovative research and development in cardiovascular, central nervous system, blood system, metabolism and digestive system, anti-infective and anti-tumor therapeutic fields. Facing the future, Fosun Pharma will adhere to the brand philosophy of "continuing to innovate and enjoy health" and continue to adhere to the development strategy of "endogenous growth, outward expansion and integrated development", and strive to become the first-class enterprise in the global mainstream medical and health market. Learn more on the FosunPharma website: https://www.fosunpharma.com/en/

NovoPedics, Inc. is developing implantable medical devices designed to relieve pain and restore mobility to patients suffering from severe meniscal injuries and meniscectomies. MeniscoFix™ is a polymer fiber-reinforced scaffold for total meniscus replacement designed to be gradually resorbed by the body and be replaced by new tissue. It represents an innovative approach to replace damaged meniscal tissue with a patented fiber-reinforced design similar to the native meniscus. It is designed to be attached to both soft tissue and bone, thus potentially enabling its use in total meniscus replacement surgery.

Nuvectis Pharma is a biopharmaceutical company that focuses on developing novel targeted therapeutics for cancer treatment, including the oral small molecule inhibitor NXP800 targeting the Heat Shock Factor 1 pathway.

Odin Pharmaceuticals LLC is a sterile pharmaceutical company that develops injectable and ophthalmic drugs for the US marketplace.

A life sciences company modernizing the way medicines are taken. Our mission is to improve patient outcomes through our next generation therapeutic delivery system, the Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. With our proprietary manufacturing processes and state of the art cGMP-compliant facility in the U.S., we have developed our first product candidate, ORAVEXX™, a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. We are empowering the medical community by partnering with leading research institutions and physicians to support multiple FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to determine the safety and efficacy of CBD for the management of pain and inflammation.

Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself against recruiting fraud from individuals, organizations or other entities claiming to represent Organon. All official Organon recruitment emails will come from accounts formatted as name@organon.com or organon@workday.com, and Organon will never conduct interviews by chat or email, or make job offers through social media or online forums. All candidates for roles at Organon will first meet with a recruiter and interview team, via Teams or in person. Organon will never ask you to make financial transactions on its behalf or ask you to receive or ship packages or goods. For more information on adverse event reporting, visit http://bit.ly/AEReporting. To read our community guidelines, visit http://bit.ly/OrganonCommunityGuidelines. Follow us on Twitter at Organon (@OrganonLLC). Follow us on Instagram at Organon (@OrganonLLC).

Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. See our community guidelines at https://www.bauschhealth.com/social-media/.

There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD). With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases. Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

At Petros, we are bringing new approaches to the most challenging conditions in men's health. We seek to understand the various health phases throughout a man’s journey. We collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality. Please see the full Prescribing Information and Patient Information: https://stendra.com/wp-content/uploads/2022/04/stendra-prescribing-information.pdf https://stendra.com/wp-content/uploads/2022/04/stendra-patient-information.pdf

PhageNova Bio is a company that has developed a targeted gene delivery vector. The company is engaged in pioneering targeted gene expression for gene therapy.

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Welcome to Regenicin specializing development regenerative cell therapies, NovaDerm®

ReGenTree, LLC is a newly created U.S. joint venture company owned by HLB Therapeutics (formerly GtreeBNT Co., Ltd.), a bio venture company in Korea. The company was founded with the aim of becoming a global leader in the pharmaceutical industry for ophthalmic disorders.

Our (re)Vision: Bring impactful ophthalmic medicines to as many patients as possible as quickly as possible. The company is pursuing products that address unmet needs, can be priced for access, and still have substantial commercial potential. reVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients. The company prioritizes areas of unmet or poorly met needs in ophthalmic disorders by repurposing approved or rescuing shelved drugs that could change patients’ lives. Repurposing or rescuing drugs allows for faster development at a reduced cost. Our lead program is a product for Stargardt disease, a retinal degenerative disease that often begins in childhood. Our candidate is a repurposed, GRAS (generally recognized as safe) cyclodextrin delivered intravitreally that could work as a first-line therapy or in combination with other products currently in development. It can be developed fast and produced at a relatively low cost. Other targets include a repurposed drug for dry eye disease, a rescued therapy for proliferative vitreoretinopathy, and a combination product to treat intraocular pressure.

RVL Pharmaceuticals (previously named Osmotica Pharmaceutical; Nasdaq: OSMT) is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population. We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Sentrimed is a clinical stage biotechnology company developing novel targeted therapies that harness cell-to-cell communication pathways essential to reviving the body's ability to recognize, immobilize and eliminate tumor cells. Sentrimed is a leader in contact normalization, a cellular communication process that enables normal cells to inhibit tumor proliferation and migration, and trigger tumor cell destruction. Tumor cell motility and survival are core issues in cancer impacting proliferation, migration, metastasis and overall patient prognosis. When mutagenesis occurs and normal cells are transformed into tumor cells, podoplanin (PDPN) is induced, disrupting normal cell-to-cell communication, and allowing tumor cells to escape contact normalization, proliferate and migrate. PDPN, a transmembrane glycoprotein receptor that is an early expressed tumor biomarker, is overexpressed in many cancers and is correlated with poor outcomes. Our lead product, MASL®, is a novel, orally dosed, bioactive lectin. MASL potently inhibits PDPN and blocks PDPN mediated activation of Cdc42 and downstream signaling important to cancer progression. MASL revives contact normalization to inhibit tumor cell proliferation and migration, and triggers destruction. MASL has demonstrated both cytostatic and cytotoxic effects on drug resistant human oral squamous cell carcinoma (OSCC) cells. Animal studies have not produced any identifiable adverse effects. The first indication we will seek is Head and Neck Cancers (HNC) which is a rapidly growing market with significant unmet needs.

SHINKEI is a clinical stage CNS (Central Nervous System) disorders focused pharmaceutical company using the 505(b)2 regulatory strategy to repurpose existing pharmaceutical products for faster and better patient outcome. We have a diversified and robust product development pipeline focus on improving a drug's administration such that it allows use in indications not previously possible, enhances the convenience, improves compliance, and/or ameliorates the side-effects profile for patients SHINKEI was co-founded by Suresh Borsadia and GP Singh, industry veterans, having the mix of commercial and scientific backgrounds. They are supported by a nimble and efficient team of professionals, advisors and consultants.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Signum’s phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. Signum has established a robust IP portfolio in the area of Signal Transduction Modulators (STMs). Signal transduction networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Signum has identified agents that perturb the two most central of these global regulatory mechanisms: G-Protein-Mediated membrane receptor signaling and Protein phosphorylation. G-Protein modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct stressful imbalances that can be detrimental to health and well-being.

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders.

Skunkworx Bio (SKWX) is a drug discovery powerhouse obsessed with building novel therapeutics for major unmet medical needs. SKWX expertise comes from two decades of molecular engineering experience with leaders in the field of biologic intervention. The company’s unique and proprietary technical platform allows for the generation of new biological entities unknown to biology and outside the human repertoire of possibilities.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.  Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).

As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process.

Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary dermal technology, so people with cancer can receive continuous treatment to live better, longer. Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are the most common blood cancers in the United States. There is no treatment to help people with CLL to stay in remission, and while advances in treatment have provided people with MM a multitude of treatment options, they struggle with long-term tolerance of high doses, which may be more effective but come with a multitude of side effects. Starton's team of some of the best in clinical development and hematology/oncology have come together to change the fate for people struggling with the impact of their diseases. If dose-related side effects can be reduced and people can tolerate maintenance therapy for decades to help stay in remission, these cancers – which were previously a death sentence – would become more akin to chronic diseases, with a long lifespan and healthy quality of life. Starton is one of the few life sciences companies funded exclusively by individual investors. We have a business model that is lower risk, faster to market and less capital intensive than biotech companies developing medicines from scratch.

Sunrise Pharma is a premier provider of safe and affordable generic medicines. Sunrise was founded and is based in the United States. Our products appear in various dosage forms across multiple therapeutic areas. We market products to all pharmaceutical channels including local and national retailers, wholesalers, distributors, health systems, and government. We understand the role of medicine in our society and we are wholly committed to supplying top notch quality products to the US pharmaceutical market. Our aim is to provide a diverse portfolio of safe and affordable generic medications to millions of patients to lead a happier and healthier life.

Tara Innovations LLC is formulation contract research organization (CRO). We specialize in product development, technology management, analysis, and process development. We do preformulation and pharmaceutical consulting. We are expert in nanotechnology.

TAXIS Pharmaceuticals is a biotech company devoted to combatting the serious and deadly societal threat of antibiotic resistance by creating therapies that address the root cause of the issue. We're developing therapies that, when used in combination with FDA-approved antibiotics, are intended to restore the efficacy of those medications. We currently have one investigational therapy that has completed Ph1 human trials, and several additional products in the pipeline.

A new treatment for cancer

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company’s lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer’s disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients' needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris' passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris' NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company's success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways including through our Diversity & Inclusion Committee and our Women's Business Council to help to ensure every employee's voice is heard. After all, it is our daily interactions with one another that build and sustain our culture which fuels our growth.

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

We Specialize in Urology and Women’s Health Care.Pain, urgency, frequency. Every day, urologic disorders continue to affect the lives of people all around us. Vaneltix is focused on providing immediate relief for patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), a disease of the lower urinary tract that predominantly affects women.

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.

Vivozon is a pharmaceutical drug development company.

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials for benefit of humans and human's best friend. Dog osteosarcoma is highly relevant to human osteosarcoma; drugs effective in the dog are highly relevant to the human. A further advantage of dogs that is crucial in cancer recurrence trials is the that fact that in dogs the cancer process is sped up, so that what happens over a time frame of a few years in humans is compressed into months in dogs.

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.

XEME Biopharma Inc. is clinical-stage company focused on developing therapeutic products in the area of active cancer immunotherapy (vaccines). This area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies). XEME Biopharma is focused on two integrated technology platforms: Aggregon® and Oncolipin. The Aggregon® technology is used in the manufacture of Oncoquest™-CLL and Oncoquest™-L, two innovative lead products of personalized (autologous) cancer vaccines for the treatment of leukemia and lymphoma, respectively. XEME's unique, disruptive, and patented technology platform has the following competitive advantages: - Indicated efficacy in previous clinical studies - Very low cost of production / high margins - Broad spectrum of potential clinical applications - personalized and off-the-shelf products - Rapid manufacturing process, less than 24 hours - Relatively low cost per dose, per patient

YARAL Pharma Inc. is the US subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they're cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service.

Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the work at Zena focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other central nervous system depressing substances such as opioids and alcohol.